- Home
- FLNC vs VERA Comparison
FLNC vs VERA Comparison
Compare FLNC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- VERA
- Stock Information
- Founded
- FLNC 2018
- VERA 2016
- Country
- FLNC United States
- VERA United States
- Employees
- FLNC N/A
- VERA N/A
- Industry
- FLNC Industrial Machinery/Components
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- VERA Health Care
- Exchange
- FLNC Nasdaq
- VERA Nasdaq
- Market Cap
- FLNC 2.4B
- VERA 2.5B
- IPO Year
- FLNC 2021
- VERA 2021
- Fundamental
- Price
- FLNC $22.01
- VERA $42.01
- Analyst Decision
- FLNC Buy
- VERA Strong Buy
- Analyst Count
- FLNC 17
- VERA 9
- Target Price
- FLNC $27.35
- VERA $53.56
- AVG Volume (30 Days)
- FLNC 1.3M
- VERA 683.6K
- Earning Date
- FLNC 11-26-2024
- VERA 11-07-2024
- Dividend Yield
- FLNC N/A
- VERA N/A
- EPS Growth
- FLNC N/A
- VERA N/A
- EPS
- FLNC N/A
- VERA N/A
- Revenue
- FLNC $2,143,395,000.00
- VERA N/A
- Revenue This Year
- FLNC $27.28
- VERA N/A
- Revenue Next Year
- FLNC $44.10
- VERA N/A
- P/E Ratio
- FLNC N/A
- VERA N/A
- Revenue Growth
- FLNC 7.87
- VERA N/A
- 52 Week Low
- FLNC $12.74
- VERA $9.68
- 52 Week High
- FLNC $27.80
- VERA $50.78
- Technical
- Relative Strength Index (RSI)
- FLNC 53.21
- VERA 52.57
- Support Level
- FLNC $20.00
- VERA $39.22
- Resistance Level
- FLNC $21.65
- VERA $50.00
- Average True Range (ATR)
- FLNC 0.96
- VERA 2.41
- MACD
- FLNC -0.08
- VERA 0.24
- Stochastic Oscillator
- FLNC 65.79
- VERA 28.53
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.